CFO4Life Group LLC Takes Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

CFO4Life Group LLC purchased a new stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 416 shares of the medical equipment provider’s stock, valued at approximately $217,000.

A number of other hedge funds also recently modified their holdings of the stock. Berbice Capital Management LLC bought a new stake in Intuitive Surgical in the 4th quarter valued at $26,000. BankPlus Trust Department acquired a new position in shares of Intuitive Surgical in the 4th quarter valued at approximately $28,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Intuitive Surgical during the 4th quarter worth approximately $31,000. MidAtlantic Capital Management Inc. acquired a new stake in shares of Intuitive Surgical in the 3rd quarter valued at $33,000. Finally, Decker Retirement Planning Inc. bought a new position in shares of Intuitive Surgical in the 4th quarter valued at $36,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Analyst Upgrades and Downgrades

ISRG has been the subject of a number of research reports. Stifel Nicolaus increased their target price on shares of Intuitive Surgical from $525.00 to $610.00 and gave the stock a “buy” rating in a report on Thursday, December 5th. Piper Sandler restated an “overweight” rating and set a $670.00 price target (up from $538.00) on shares of Intuitive Surgical in a report on Friday, January 24th. Erste Group Bank raised Intuitive Surgical from a “hold” rating to a “buy” rating in a research report on Tuesday, November 19th. Barclays boosted their price target on shares of Intuitive Surgical from $610.00 to $674.00 in a research report on Monday, January 27th. Finally, Royal Bank of Canada boosted their price objective on Intuitive Surgical from $611.00 to $641.00 in a research note on Monday, January 27th. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $613.10.

Insider Buying and Selling

In other news, CFO Jamie Samath sold 94 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $571.11, for a total transaction of $53,684.34. Following the completion of the transaction, the chief financial officer now directly owns 2,630 shares of the company’s stock, valued at $1,502,019.30. This represents a 3.45 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Brian Edward Miller sold 8,900 shares of the firm’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $485.07, for a total value of $4,317,123.00. Following the completion of the sale, the executive vice president now directly owns 5,758 shares of the company’s stock, valued at $2,793,033.06. This represents a 60.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 22,209 shares of company stock worth $11,928,127. 0.90% of the stock is owned by insiders.

Intuitive Surgical Trading Down 4.1 %

Shares of Intuitive Surgical stock opened at $476.78 on Friday. The stock has a fifty day simple moving average of $568.47 and a 200 day simple moving average of $531.22. The company has a market capitalization of $169.82 billion, a P/E ratio of 74.38, a price-to-earnings-growth ratio of 5.85 and a beta of 1.43. Intuitive Surgical, Inc. has a 12-month low of $364.17 and a 12-month high of $616.00.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.